Xin Xu

TL;DR: In this article, the authors used a quantitative high-throughput screen to identify small-molecule PHGDH inhibitors, which reduced the incorporation into nucleotides of one-carbon units from glucose-derived and exogenous serine.

TL;DR: It is concluded that targeting NRF2 may represent a promising strategy for the treatment of advanced NSCLC because of its high specificity and selectivity and its ability to bind to and inhibit its downstream target gene expression.

TL;DR: This open-label, dose-escalation phase 1-2a study gave monthly intrathecal HPβCD to participants with NPC1 with neurological manifestation at the National Institutes of Health and evaluated Serum and CSF 24(S)-hydroxycholesterol (24[S]-HC), which serves as a biomarker of target engagement, andCSF protein biomarkers were evaluated.

TL;DR: HS is established as an attachment factor that assists SARS coronavirus cell entry and reveals drugs capable of targeting this important step in the viral life cycle.

TL;DR: How this collaborative effort helped to overcome scientific, clinical and financial challenges facing the development of new drug treatments for rare and neglected diseases, and how it will incentivize the commercialization of HP-β-CD for the benefit of the NPC patient community are discussed are discussed.